WO2005118580A3 - Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique - Google Patents

Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique Download PDF

Info

Publication number
WO2005118580A3
WO2005118580A3 PCT/US2005/016569 US2005016569W WO2005118580A3 WO 2005118580 A3 WO2005118580 A3 WO 2005118580A3 US 2005016569 W US2005016569 W US 2005016569W WO 2005118580 A3 WO2005118580 A3 WO 2005118580A3
Authority
WO
WIPO (PCT)
Prior art keywords
tricyclic compounds
inhibitors
signaling pathway
activity
hypoxic signaling
Prior art date
Application number
PCT/US2005/016569
Other languages
English (en)
Other versions
WO2005118580A2 (fr
Inventor
Giovanni Melillo
Robert H Shoemaker
John H Cardellina
Michael J Currens
Mark Creighton-Gutteridge
Badarch Uranchimeg
Annamaria Rapisarda
Dominic A Scudiero
Original Assignee
Us Gov Health & Human Serv
Giovanni Melillo
Robert H Shoemaker
John H Cardellina
Michael J Currens
Mark Creighton-Gutteridge
Badarch Uranchimeg
Annamaria Rapisarda
Dominic A Scudiero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Giovanni Melillo, Robert H Shoemaker, John H Cardellina, Michael J Currens, Mark Creighton-Gutteridge, Badarch Uranchimeg, Annamaria Rapisarda, Dominic A Scudiero filed Critical Us Gov Health & Human Serv
Publication of WO2005118580A2 publication Critical patent/WO2005118580A2/fr
Publication of WO2005118580A3 publication Critical patent/WO2005118580A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/24—[b,e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • C07D241/48—Phenazines with hydrocarbon radicals, substituted by nitrogen atoms, directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/36—[b, e]-condensed, at least one with a further condensed benzene ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur des composés tricycliques qui inhibent sélectivement l'activité de HIF-l?. L'invention porte également sur des méthodes visant à réduire l'activité de HIF-1? et inhiber l'angiogenèse, la tumorigenèse et/ou la métastase chez un sujet. Selon certains modes de mise en oeuvre, les composés tricycliques inhibent curieusement l'activité de HIF-l? à des concentrations non cytotoxiques, ce qui évite les effets secondaires des médicaments associés à une cytotoxicité importante.
PCT/US2005/016569 2004-05-12 2005-05-11 Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique WO2005118580A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57061504P 2004-05-12 2004-05-12
US60/570,615 2004-05-12
US61827904P 2004-10-12 2004-10-12
US60/618,279 2004-10-12

Publications (2)

Publication Number Publication Date
WO2005118580A2 WO2005118580A2 (fr) 2005-12-15
WO2005118580A3 true WO2005118580A3 (fr) 2006-08-03

Family

ID=35447501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016569 WO2005118580A2 (fr) 2004-05-12 2005-05-11 Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique

Country Status (1)

Country Link
WO (1) WO2005118580A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
WO2009043093A1 (fr) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Inhibition de hif
EP2085390A1 (fr) 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Analogues d'halobenzamide marqués en tant que produits radiopharmaceutiques multimodaux et leurs précurseurs
WO2010018458A2 (fr) * 2008-08-12 2010-02-18 Crystalgenomics, Inc. Dérivés de phénol et leurs procédés d'utilisation
WO2010075869A1 (fr) * 2008-12-30 2010-07-08 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides et leur utilisation
EP2440048B8 (fr) 2009-06-09 2015-12-16 NantBioScience, Inc. Dérivés de l'isoquinoléine, de la quinoléine et de la quinazoléine servant d'inhibiteurs de signal hedgehog
BRPI1011319A2 (pt) 2009-06-09 2016-06-21 California Capital Equity Llc derivados de triazina benzil-substituídos e suas aplicações terapêuticas
BRPI1011318A2 (pt) 2009-06-09 2019-09-24 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas
EP2977050A1 (fr) 2010-10-08 2016-01-27 Nivalis Therapeutics, Inc. Nouveaux composés quinoléine substitués comme inhibiteurs de la s-nitrosoglutathione réductase
US8785643B2 (en) 2010-12-16 2014-07-22 N30 Pharmaceuticals, Inc. Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
HUE059324T2 (hu) 2015-11-06 2022-11-28 Incyte Corp Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
IL295978B1 (en) 2017-10-18 2023-09-01 Incyte Corp Concentrated imidazole derivatives substituted by tertiary hydroxy groups as P13K-gamma inhibitors
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
EP4364798A2 (fr) 2018-10-05 2024-05-08 Annapurna Bio Inc. Composés et compositions pour le traitement d'états associés à l'activité du récepteur apj
WO2021158495A1 (fr) * 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Composés de benzo[5,6] [1,4]dioxino[2,3-b]pyridine utiles en tant qu'inhibiteurs de l'irak4

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098098A2 (fr) * 1982-06-25 1984-01-11 Development Finance Corporation Of New Zealand Composés acridinecarboxamidiques
EP0172744A2 (fr) * 1984-08-16 1986-02-26 Development Finance Corporation Of New Zealand Composés de phénazinecarboxamide
EP0206802A2 (fr) * 1985-06-24 1986-12-30 Cancer Research Campaign Technology Limited Dérivés de quinoléine substitués
WO2002100843A1 (fr) * 2001-06-13 2002-12-19 Jianqing Lu Composes phenoxazines, preparations les contenant et leurs utilisations medicinales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098098A2 (fr) * 1982-06-25 1984-01-11 Development Finance Corporation Of New Zealand Composés acridinecarboxamidiques
EP0172744A2 (fr) * 1984-08-16 1986-02-26 Development Finance Corporation Of New Zealand Composés de phénazinecarboxamide
EP0206802A2 (fr) * 1985-06-24 1986-12-30 Cancer Research Campaign Technology Limited Dérivés de quinoléine substitués
WO2002100843A1 (fr) * 2001-06-13 2002-12-19 Jianqing Lu Composes phenoxazines, preparations les contenant et leurs utilisations medicinales

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ATWELL G J ET AL: "POTENTIAL ANTITUMOR AGENTS. 57. 2-PHENYLQUINOLINE-8-CARBOXAMIDES AS MINIMAL DNA-INTERCALATING ANTITUMOR AGENTS WITH IN VIVO SOLID TUMOR ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 32, no. 2, 1989, pages 396 - 401, XP001071285, ISSN: 0022-2623 *
DATABASE WPI Section Ch Week 200318, Derwent World Patents Index; Class B02, AN 2003-183933, XP002379936 *
DENNY W A ET AL: "POTENTIAL ANTITUMOR AGENTS 59. STRUCTURE-ACTIVITY RELATIONSHIPS FOR 2-PHENYLBENZIMIDAZOLE-4-CARB OXAMIDES, A NEW CLASS OF MINIMAL DNA-INTERCALATING AGENTS WHICH MAY NOT ACT VIA TOPOISOMERASE II", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 2, 1 February 1990 (1990-02-01), pages 814 - 819, XP002007402, ISSN: 0022-2623 *
DENNY W A ET AL: "POTENTIAL ANTITUMOR AGENTS. 49. 5-SUBSTITUTED DERIVATIVES OF N-2-(DIMETHYLAMINO)ETHYL-9-AMINOACRIDINE-4-CARBOXAMIDE WITH IN VIVO SOLID-TUMOR ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 30, no. 4, 1986, pages 658 - 663, XP001024208, ISSN: 0022-2623 *
HO H. LEE ET AL: "Potentail Antitumor Agents. 64. Synthesis and Antitumor Evaluation of Dibenzo[1,4]dioxin-1-carboxamides: A New Class of Weakly Binding DNA-Intercalating Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, 1992, pages 258 - 266, XP002379888 *
KRISHNAMACHARY B ET AL: "Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 5, 1 March 2003 (2003-03-01), pages 1138 - 1143, XP002341115, ISSN: 0008-5472 *
KUNG A L ET AL: "Suppression of tumor growth through disruption of hypoxia-inducible transcription", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 12, December 2000 (2000-12-01), pages 1335 - 1340, XP002328150, ISSN: 1078-8956 *
MAXWELL P H ET AL: "Hypoxia -inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, July 1997 (1997-07-01), pages 8104 - 8109, XP002124649, ISSN: 0027-8424 *
PALMER B D ET AL: "POTENTIAL ANTITUMOR AGENTS. 54. CHROMOPHORE REQUIREMENTS FOR IN VIVO ANTITUMOR ACTIVITY AMONG THE GENERAL CLASS OF LINEAR TRICYCLICCARBOXAMIDES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 31, no. 4, 1988, pages 707 - 712, XP002059942, ISSN: 0022-2623 *
PAWLAK K ET AL: "CYTOTOXIC AND ANTITUMOR ACTIVITY OF 1-NITROACRIDINES AS AN AFTEREFFECT OF THEIR INTERSTRAND DNA CROSS-LINKING", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 44, no. 10, October 1984 (1984-10-01), pages 4289 - 4296, XP001008685, ISSN: 0008-5472 *
REWCASTLE G W ET AL: "POTENTIAL ANTITUMOR AGENTS. 51. SYNTHESIS AND ANITITUMOR ACITIVITY OF SUBSTITUTED PHENAZINE-1-CARBOXAMIDES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 30, no. 5, 1987, pages 843 - 851, XP002051604, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2005118580A2 (fr) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005118580A3 (fr) Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique
WO2007059111A3 (fr) Activite antiangiogenese du 2-methoxyestradiol en combinaison avec des agents anticancereux
WO2005070930A3 (fr) Composes de tetrahydrocarboline comme agents anticancereux
MX2007006178A (es) Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular.
WO2005110477A3 (fr) Polytherapies pour le cancer et des angiopathies proliferantes
WO2005004808A3 (fr) Composes tetracycliques utilises comme inhibiteurs de c-met
TW200738240A (en) Pharmaceutical compositions
WO2005067901A3 (fr) Methodes permettant de traiter et de prevenir l'hypertension et les troubles associes a l'hypertension
WO2006012642A3 (fr) Derives de pyrrole en tant qu'agents pharmaceutiques
EP1809109A4 (fr) Produit nutritif a faible activite d'eau presentant un contenu microbien benefique et une haute teneur en huile
WO2005042700A3 (fr) Utilisation d'inhibiteurs de la voie hedgehog dans le cancer pulmonaire à petites cellules
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2008112199A8 (fr) Procédé d'inhibition de la topoisomérase ii
WO2007126957A3 (fr) Nouveaux composés
WO2007008200A8 (fr) Analogues de wortmannin et methodes d'utilisation de ceux-ci en combinaison avec des agents chimiotherapeutiques
WO2008097546A3 (fr) Composés inhibiteurs de cholinestérase
MY148723A (en) Use of pinolenic acid for the treatment of obesity
WO2005009387A3 (fr) Derives de l'azepine comme agents pharmaceutiques
WO2006020680A3 (fr) Composes heterocycliques comme agents pharmaceutiques
TW200700071A (en) Novel use
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
AU2003228796A1 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
PL1708711T3 (pl) Kompozycje użyteczne zwłaszcza w leczeniu lub zapobieganiu zespołowi metabolicznemu
EP1877352A4 (fr) Methodes, composes et compositions a activite anticancereuse selective relative au genotype
WO2006102375A3 (fr) Methodes pour eviter un oedeme dans le traitement ou la prevention de maladies sensibles a ppar$g(g), telles que le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase